Cetuximab plus irinotecan,fluorouracil,and leucovorin(FOLFIRI)represents a first-line therapeutic standard for RAS/BRAF wild-type metastatic colorectal cancer(mCRC)patients.Despite this established approach,cetuximab...Cetuximab plus irinotecan,fluorouracil,and leucovorin(FOLFIRI)represents a first-line therapeutic standard for RAS/BRAF wild-type metastatic colorectal cancer(mCRC)patients.Despite this established approach,cetuximabβ(CMAB009),as a modified antibody of cetuximab,prospectively selected for dual RAS/BRAF wild-type patients,has not yet been validated in the Chinese mCRC patients through phase 3 trial.In this study(ClinicalTrials.gov identifier:NCT03206151),patients with RAS/BRAF wild-type mCRC who were not suitable for radical resection were randomly assigned in a 1:1 ratio to receive cetuximabβplus FOLFIRI or FOLFIRI alone.The primary endpoint was blinded independent review committee-assessed progression-free survival(PFS).The secondary endpoints included overall survival(OS),objective response rate(ORR),disease control rate(DCR),surgery rate for metastasis and R0 resection rate,and safety.From January 4,2018 to September 2,2021,a total of 505 eligible patients were enrolled and received study treatment;the median follow-up duration was 8.7 months(95%confidence interval[Cl],7.77 to 9.29)and 5.9 months(95%CI,5.63 to 6.65)in cetuximabβplus FOLFIRI group and FOLFIRI group,respectively.Compared to FOLFIRI alone,cetuximabβplus FOLFIRI demonstrated statistically significant improvements in median PFS(13.1 vs.9.6 months,hazard ratio[HR],0.639;95%CI,0.468 to 0.872;P=0.004),median OS(28.3 vs.23.1 months,HR,0.729;95%CI,0.551 to 0.965;P=0.024),and ORR(69.1%vs.42.3%,odds ratio,3.090;95%CI,2.280 to 4.189;P<0.001).Cetuximabβplus FOLFIRI exhibited manageable toxicity without novel safety signals.This study demonstrated that cetuximabβplus FOLFIRI provided significant clinical benefits as a first-line treatment for patients with RAS/BRAF wild-type mCRC.Compared to FOLFIRI alone,cetuximabβplus FOLFIRI therapy led to prolonged median PFS and OS while maintaining a manageable safety profle,offering a new treatment option for this patient population.展开更多
文摘Cetuximab plus irinotecan,fluorouracil,and leucovorin(FOLFIRI)represents a first-line therapeutic standard for RAS/BRAF wild-type metastatic colorectal cancer(mCRC)patients.Despite this established approach,cetuximabβ(CMAB009),as a modified antibody of cetuximab,prospectively selected for dual RAS/BRAF wild-type patients,has not yet been validated in the Chinese mCRC patients through phase 3 trial.In this study(ClinicalTrials.gov identifier:NCT03206151),patients with RAS/BRAF wild-type mCRC who were not suitable for radical resection were randomly assigned in a 1:1 ratio to receive cetuximabβplus FOLFIRI or FOLFIRI alone.The primary endpoint was blinded independent review committee-assessed progression-free survival(PFS).The secondary endpoints included overall survival(OS),objective response rate(ORR),disease control rate(DCR),surgery rate for metastasis and R0 resection rate,and safety.From January 4,2018 to September 2,2021,a total of 505 eligible patients were enrolled and received study treatment;the median follow-up duration was 8.7 months(95%confidence interval[Cl],7.77 to 9.29)and 5.9 months(95%CI,5.63 to 6.65)in cetuximabβplus FOLFIRI group and FOLFIRI group,respectively.Compared to FOLFIRI alone,cetuximabβplus FOLFIRI demonstrated statistically significant improvements in median PFS(13.1 vs.9.6 months,hazard ratio[HR],0.639;95%CI,0.468 to 0.872;P=0.004),median OS(28.3 vs.23.1 months,HR,0.729;95%CI,0.551 to 0.965;P=0.024),and ORR(69.1%vs.42.3%,odds ratio,3.090;95%CI,2.280 to 4.189;P<0.001).Cetuximabβplus FOLFIRI exhibited manageable toxicity without novel safety signals.This study demonstrated that cetuximabβplus FOLFIRI provided significant clinical benefits as a first-line treatment for patients with RAS/BRAF wild-type mCRC.Compared to FOLFIRI alone,cetuximabβplus FOLFIRI therapy led to prolonged median PFS and OS while maintaining a manageable safety profle,offering a new treatment option for this patient population.
